![](https://globalalzplatform.org/wp-content/uploads/2020/05/KU-ADC-300x62.png)
KU Alzheimer’s Disease Center Team Earns Diversity, Equity and Inclusion Award
GAP-Net Site, the University of Kansas Alzheimer’s Disease Center’s (KU ADC) Outreach, Recruitment and Education Core earned the 2020 University of Kansas Medical Center Diversity, Equity and Inclusion Award. The University of Kansas Alzheimer’s Disease Center’s Outreach, Recruitment and Education Core earned the 2020 University of Kansas Medical Center Diversity, Equity and Inclusion Award. Presented […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2020/05/MA-ARDC-300x294.jpg)
Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During Early Stages of Alzheimer’s Disease
Dorene M. Rentz, PsyD, from GAP-Net site Brigham and Women’s Center for Alzheimer’s Research and Treatment, and Professor of Neurology at Harvard Medical School co-authored Costs of Early Stage Alzheimer’s Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1. You can find the study posted in The Journal of Alzheimer’s Disease […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2020/04/Screen-Shot-2020-04-03-at-2.44.30-PM.png)
Coronavirus Takes its Toll on Alzheimer’s Clinical Trials
Global Alzheimer’s Platform Foundation president, John Dwyer, was quoted on how GAP is supporting GAP-Net sites during the COVID-19 pandemic, emphasizing the importance of safety and remote clinical trial testing. The coronavirus pandemic is upending not only life as we knew it, but Alzheimer’s clinical studies as well. In the United States, Europe, and Australia, […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2020/03/Screen-Shot-2020-03-05-at-2.09.46-PM-300x48.png)
When a Drug Study Abruptly Ends, Volunteers Are Left to Cope
A participant might commit months or years to a drug trial, only to see it vanish overnight. On March 21, 2019, the staff at the Penn Memory Center in Philadelphia was scrambling to learn more about an early-morning announcement: Two pharmaceutical companies, Biogen and Eisai, would discontinue their clinical trial of a drug intended to […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2020/03/Screen-Shot-2020-03-05-at-2.04.55-PM-300x87.png)
Researchers Struggling to Find Alzheimer’s Clinical Trial Participants
A site in the Global Alzheimer’s Platform Foundation’s network, ClinCloud Clinical Research, was featured on FOX35 Orlando on March 4, 2020 at 6pm. Click here to watch the segment. MAITLAND, Fla. – Researchers have been spending years trying to cure Alzheimer’s Disease. We’ve seen several medical breakthroughs in Central Florida, but they are still running into problems. They […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2020/03/Screen-Shot-2020-03-03-at-12.03.30-PM-300x93.png)
Alzheimer’s Studies in Central Florida Need More African Americans
This past week, the Global Alzheimer’s Platform Foundation, which works with a national network of clinical research centers, held its annual Site Optimization Conference in Orlando. The conference brings together the leaders of more than 80 clinical trial sites throughout the U.S. and Canada who work day in and day out to identify a cure […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2020/02/151022_GAPF_Full_Logo_Color-1-300x127.jpg)
Hispanics to Volunteer in Alzheimer’s Studies
A Spanish translation of the article below can be found on Orlando Sentenial posted on February 27, 2020 by Ginayra Alvarado Villegas. According to statistics from the Alzheimer’s Association in the United States, every 65 seconds a person develops Alzheimer’s disease, a disease that has doctors and researchers conducting studies to develop a drug or […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2020/02/Blue_Cross_Blue_Shield_Association_Logo-300x144.jpg)
Early-Onset Dementia and Alzheimer’s Diagnoses Spiked 373 Percent for Generation X and Millennials
CHICAGO, Feb. 27, 2020 /PRNewswire/ — The number of commercially insured Americans age 30 to 64 diagnosed with early-onset dementia or Alzheimer’s disease increased by 200% from 2013 to 2017. The average age of a person living with either form of dementia is 49. The findings came from a new Blue Cross Blue Shield Association (BCBSA) report, “Early-Onset […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2020/02/Screen-Shot-2020-02-14-at-11.50.31-AM-300x115.png)
Investors Meet Opportunity at Inaugural Global Alzheimer’s Platform Foundation Innovation Summit
At a pivotal time in Alzheimer’s research, the GAP Foundation and the Alzheimer’s Drug Discovery Foundation will connect funders with leading innovators Updated on March 26, 2020: The Global Alzheimer’s Platform Foundation (GAP) has announced it is postponing the GAP Innovation Summit that was to be held on May 5, 2020 with our partner, the […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2020/01/Georgetown-University1-300x100.png)
Georgetown’s Alzheimer’s Clinic Marks 20 Years, but Hopes Research can Make it Obsolete.
The Global Alzheimer’s Platform Foundation recognizes the impact that GAP-Net site Georgetown University Medical Center’s Memory Disorders Program has had on Alzheimer’s disease research. We congratulate them on their 20 years of dedication and service to the field. WASHINGTON (WJLA) — It’s estimated that one in 10 people 65 and over has Alzheimer’s disease. That’s nearly […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2019/07/brain-300x212.png)
Rhode Island’s Man of the Year for 2019
The Global Alzheimer’s Platform Foundation is proud and honored to work with GAP Net site Butler Hospital Memory and Aging Program’s Dr. Stephen Salloway, who was named Rhode Island’s Man of the Year for 2019. It is the cruelest of diseases. It is the sixth leading cause of death in America. In the United States, […]
Read more »